Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87% of patients with stage III melanoma remained alive, according to new results from a study led by researchers at The University of Texas MD Anderson Cancer Center.

A breast scan for detecting cancer takes less than a minute using an experimental system that combines photoacoustic and ultrasound imaging, according to a study in IEEE Transactions on Medical Imaging. The system does not require painful compression like mammography. In tests, it produced clear, artificial intelligence-powered 3D images of common breast cancer subtypes such as Luminal A, Luminal B and Triple-Negative Breast Cancer.

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an immunotherapy drug) plus gemcitabine and cisplatin (GemCis, chemotherapy drugs) as the first-line treatment for people with advanced biliary tract cancer (aBTC), researchers have shown that after three years more than twice as many study participants treated with durvalumab plus GemCis had survived compared to those treated with a placebo plus GemCis. The new results in the Journal of Hepatology, published by Elsevier, establish a new survival benchmark for people living with aBTC and reinforce durvalumab plus GemCis as a standard of care for first-line treatment for aBTC.

CZI announced its latest AI model, GREmLN, aimed at helping researchers better understand how cells behave by focusing on the key networks that control cell behavior.